查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726201

抗糖尿病藥物市場規模、佔有率、趨勢分析報告：按藥物類別、糖尿病類型、給藥途徑、分銷管道、地區和細分市場進行預測，2025 年至 2030 年

Antidiabetics Market Size, Share & Trends Analysis Report By Drug Class, By Diabetes Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

抗糖尿病藥物市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球抗糖尿病藥物市場規模預計到2030年將達到1,685.5億美元，2025年至2030年期間的複合年成長率為10.75%。

糖尿病盛行率的不斷上升是該市場的主要驅動力。不規則的飲食習慣和日益嚴重的肥胖症也可能導致目標疾病發病率上升，從而刺激對該產品的需求。目前正在研發的產品的未來商業化以及亞太和拉丁美洲新興市場中的巨大未開發機會預計將推動未來幾年的市場成長。

胰島素是盈利最高的細分市場，2013 年市場規模超過 200 億美元。胰島素也是該市場中最賺錢的細分市場之一。推出具有更高功效的新產品以及政府推出的有利舉措是增加市場吸引力的因素。

抗糖尿病藥物市場報告重點

  • 新核准的DPP-4 抑制劑，包括 Januvia、Nesina 和 Onglyza，由於其每日一次的給藥方案和安全性，已迅速滲透到市場。
  • 北美是最成熟的抗糖尿病藥物市場，2024 年佔 41.48% 的市場。胰島素和其他抗糖尿病藥物的高市場滲透率以及完善的報銷制度預計將推動該地區的市場成長。
  • 預計亞太地區將為製造商提供豐厚的未來成長機會。大量未滿足的醫療需求和醫療基礎設施的快速改善預計將成為該地區市場成長的促進因素。此外，當地製造商推出的更便宜的產品也有望推動市場發展。
  • 抗糖尿病藥物市場的主要參與企業包括阿斯特捷利康公司、拜耳公司、工業、禮來公司、勃林格殷格翰公司、百時美施貴寶公司、默克公司、強生服務公司和輝瑞公司。
  • 該市場本質上是寡占的，少數公司控制著70%以上的市場。旨在開發新產品和透過政府合約進入市場的大量研發投資是這些公司採用的主要永續性策略。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
  • 市場趨勢與展望
  • 市場動態
    • 糖尿病盛行率上升
    • 研究和技術進步
    • 提高認知和早期療育
  • 市場限制因素分析
    • 開發成本高
    • 副作用和安全問題
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
  • 定價分析
  • 管道分析

4. 抗糖尿病藥物市場-藥物類別業務分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年藥品類別市場規模、預測及趨勢分析
  • 胰島素
  • GLP-1受體促效劑
  • DPP-4抑制劑
  • SGLT2抑制劑
  • DPP-4抑制劑
  • 其他

第5章抗糖尿病藥物市場：糖尿病類型的商業分析

  • 2024 年及 2030 年糖尿病類型市場佔有率
  • 糖尿病類型細分儀表板
  • 市場規模、預測與趨勢分析（按糖尿病類型，2018-2030 年）
  • 類型 1
  • 類型 2

6. 抗糖尿病藥物市場：給藥途徑業務分析

  • 2024 年及 2030 年給藥途徑市場佔有率
  • 給藥途徑細分儀表板
  • 按管理路線分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 口服
  • 皮下
  • 靜脈

7. 抗糖尿病藥物市場：通路業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 網路藥局
  • 醫院藥房
  • 零售藥局

第8章抗糖尿病藥物市場：區域、估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Novo Nordisk
    • Eli Lilly and Company
    • Sanofi
    • Merck & Co., Inc.
    • AstraZeneca plc
    • Johnson & Johnson Services Inc.
    • Boehringer Ingelheim
    • Novartis AG
    • Takeda Pharmaceutical Company
    • Bayer AG
Product Code: 978-1-68038-304-1

Antidiabetics Market Growth & Trends:

The global antidiabetics market size is expected to reach USD 168.55 billion by 2030, expanding at a CAGR of 10.75% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights:

  • The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
  • North America was the most mature antidiabetics market in 2024 accounting for over 41.48% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
  • Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
  • Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
  • The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Diabetes Type
    • 1.2.3. Distribution Channel
    • 1.2.4. Route of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Rising Diabetes Prevalence
    • 3.3.2. Advancements in Research and Technology
    • 3.3.3. Increasing Awareness and Early Intervention
  • 3.4. Market Restraint Analysis
    • 3.4.1. High Development Costs
    • 3.4.2. Side Effects and Safety Concerns
  • 3.5. Industry Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
  • 3.6. Pricing Analysis
  • 3.7. Pipeline Analysis

Chapter 4. Antidiabetics Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Insulin
    • 4.4.1. Insulin Market, 2018 - 2030 (USD Million)
      • 4.4.1.1. Insulin Market, By Type
        • 4.4.1.1.1. Long-acting insulin
          • 4.4.1.1.1.1. Long-acting insulin market, 2018 - 2030 (USD Million)
        • 4.4.1.1.2. Premix insulin
          • 4.4.1.1.2.1. Premix insulin market, 2018 - 2030 (USD Million)
        • 4.4.1.1.3. Fast-acting insulin
          • 4.4.1.1.3.1. Fast-acting insulin market, 2018 - 2030 (USD Million)
        • 4.4.1.1.4. Human insulin
          • 4.4.1.1.4.1. Human insulin market, 2018 - 2030 (USD Million)
  • 4.5. GLP-1 Receptor Agonists
    • 4.5.1. GLP-1 Receptor Agonists Market, 2018 - 2030 (USD Million)
  • 4.6. DPP- 4 Inhibitors
    • 4.6.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.7. SGLT2 Inhibitors
    • 4.7.1. SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. DPP-4 Inhibitors
    • 4.8.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Antidiabetics Market: Diabetes Type Business Analysis

  • 5.1. Diabetes Type Market Share, 2024 & 2030
  • 5.2. Diabetes Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Diabetes Type , 2018 to 2030 (USD Million)
  • 5.4. Type 1
    • 5.4.1. Type 1 Market, 2018 - 2030 (USD Million)
  • 5.5. Type 2
    • 5.5.1. Type 2 Market, 2018 - 2030 (USD Million)

Chapter 6. Antidiabetics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.5. Subcutaneous
    • 6.5.1. Subcutaneous Market, 2018 - 2030 (USD Million)
  • 6.6. Intravenous
    • 6.6.1. Intravenous Market, 2018 - 2030 (USD Million)

Chapter 7. Antidiabetics Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Online Pharmacies
    • 7.4.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Hospital Pharmacies
    • 7.5.1. Hospital Pharmacies, Market, 2018 - 2030 (USD Million)
  • 7.6. Retail Pharmacies
    • 7.6.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Antidiabetics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Antidiabetics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novo Nordisk
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Eli Lilly and Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Sanofi
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Merck & Co., Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. AstraZeneca plc
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Johnson & Johnson Services Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Boehringer Ingelheim
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Novartis AG
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Takeda Pharmaceutical Company
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Bayer AG
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global antidiabetics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 Global antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 4 Global antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Global antidiabetics market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 North America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 10 North America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 North America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 U.S. antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 14 U.S. antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Canada antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 18 Canada antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Canada antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Mexico antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 21 Mexico antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 22 Mexico antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Mexico antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Europe antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 25 Europe antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 Europe antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 27 Europe antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Europe antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 UK antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 31 UK antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 UK antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Germany antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 Germany antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 35 Germany antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Germany antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 France antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 France antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 39 France antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 France antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Italy antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 Italy antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 43 Italy antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Italy antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Spain antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 46 Spain antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 47 Spain antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Spain antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Denmark antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 50 Denmark antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 51 Denmark antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Denmark antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Sweden antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 Sweden antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 55 Sweden antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Sweden antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Norway antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 58 Norway antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 59 Norway antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Norway antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Japan antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 Japan antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 68 Japan antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Japan antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 China antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 71 China antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 72 China antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 China antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 India antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 75 India antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 76 India antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 India antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Australia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 79 Australia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 80 Australia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 81 Australia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Thailand antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 Thailand antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 84 Thailand antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 Thailand antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 South Korea antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 87 South Korea antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 88 South Korea antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 South Korea antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 91 Latin America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 92 Latin America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 93 Latin America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Latin America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Brazil antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 96 Brazil antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 97 Brazil antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Brazil antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 100 Argentina antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 101 Argentina antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 Argentina antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 109 South Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 110 South Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 111 South Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 117 UAE antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 118 UAE antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 UAE antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 123 Kuwait antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Antidiabetics market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global antidiabetics market: drug class movement analysis
  • Fig. 16 Global antidiabetics market, for Insulin, 2018 - 2030 (USD Million)
  • Fig. 17 Global antidiabetics market, for GLP-1 receptor agonists, 2018 - 2030 (USD Million)
  • Fig. 18 Global antidiabetics market, for DPP- 4 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 19 Global antidiabetics market, for SGLT2 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 20 Global antidiabetics market, for others, 2018 - 2030 (USD Million)
  • Fig. 21 Global antidiabetics market: diabetes type movement analysis
  • Fig. 22 Global antidiabetics market, for type 1, 2018 - 2030 (USD Million)
  • Fig. 23 Global antidiabetics market, for type 2, 2018 - 2030 (USD Million)
  • Fig. 24 Global antidiabetics market: route of administration movement analysis
  • Fig. 25 Global antidiabetics market, for oral, 2018 - 2030 (USD Million)
  • Fig. 26 Global antidiabetics market, for subcutaneous, 2018 - 2030 (USD Million)
  • Fig. 27 Global antidiabetics market, for intravenous, 2018 - 2030 (USD Million)
  • Fig. 28 Global antidiabetics market: distribution channel movement analysis
  • Fig. 29 Global antidiabetics market, for online pharmacies, 2018 - 2030 (USD Million)
  • Fig. 30 Global antidiabetics market, for hospital pharmacies, 2018 - 2030 (USD Million)
  • Fig. 31 Global antidiabetics market, retail pharmacies, 2018 - 2030 (USD Million)
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional outlook, 2024 & 2030
  • Fig. 34 Global antidiabetics market: region movement analysis
  • Fig. 35 North America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 41 UK antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 42 France antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 49 Japan antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 50 China antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 51 India antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 52 Australia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 54 Thailand antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 55 Latin America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 56 Brazil antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait antidiabetics market, 2018 - 2030 (USD Million)